Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions

By  

Drug Metabolism Letters, Vol. 10, Iss. 1, 2016-03 ,pp. : 38-48

Bentham Science Publishers

Access to resources Recommend Favorite

Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis

By Vaddi Kris   Sarlis Nicholas J   Gupta Vikas  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 16, 2012-11 ,pp. : 2397-2407

Informa Healthcare

Access to resources Recommend Favorite

Effect of food on the bioavailability and tolerability of the JAK2‐selective inhibitor fedratinib (SAR302503): Results from two phase I studies in healthy volunteers

By  

Clinical Pharmacology In Drug Development, Vol. 4, Iss. 4, 2015-07 ,pp. : 315-321

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical pharmacology of celecoxib, a COX-2 selective inhibitor

By Antoniou Katerina   Malamas Michael   Drosos Alexandros A  

Expert Opinion on Pharmacotherapy, Vol. 8, Iss. 11, 2007-08 ,pp. : 1719-1732

Informa Healthcare

Access to resources Recommend Favorite

Zoniporide: a potent and highly selective inhibitor of human Na + /H + exchanger-1

By Marala R.B.   Brown J.A.   Kong J.X.   Tracey W.R.   Knight D.R.   Wester R.T.   Sun D.   Kennedy S.P.   Hamanaka E.S.   Ruggeri R.B.   Hill R.J.  

European Journal of Pharmacology, Vol. 451, Iss. 1, 2002-09 ,pp. : 37-41

Elsevier

Access to resources Recommend Favorite